The Paradox of NET Involvement in the Pathogenesis of Inflammatory Bowel Disease [0.03%]
NETs在炎症性肠病发病机制中的悖论
Harriet Comer-Calder,Hassan O J Morad
Harriet Comer-Calder
Inflammatory bowel disease (IBD), namely Crohn's disease (CD) and ulcerative colitis (UC), are defined by chronic, non-resolving inflammation of the intestinal mucosa. Neutrophils are the first responders in inflammation, executing various ...
Real-World Effectiveness of and Optimization Strategies for Mirikizumab in Pediatric Ulcerative Colitis: A Prospective, Observational Study [0.03%]
真实世界中Mirikizumab治疗儿科溃疡性结肠炎的有效性和优化策略：一项前瞻性观察研究
Keisuke Jimbo,Nobuyasu Arai,Mitsuyoshi Suzuki et al.
Keisuke Jimbo et al.
Background: Real-world evidence for mirikizumab (MIRI) in pediatric ulcerative colitis (UC) is limited. We evaluate the real-world effectiveness, remission kinetics, and optimization strategies for MIRI in pediatric UC. ...
Gillian S Schuurman,Fiona D M van Schaik
Gillian S Schuurman
Looking Beyond the Mucosa: A New Scoring System for Mesenteric Fat in Intestinal Ultrasound [0.03%]
超越黏膜：肠道超声检查中网膜脂肪的新评分系统
Cindy C Y Law,Ashwin N Ananthakrishan
Cindy C Y Law
Association of Spondyloarthritis With Chronic Opioid Use in Inflammatory Bowel Disease: A Nationwide Danish Cohort Study [0.03%]
一项全国性丹麦队列研究：脊柱关节炎与炎症性肠病慢性阿片类药物使用之间的关联
Rahul S Dalal,Kevin Erichsen Zeiss,Jan Nielsen et al.
Rahul S Dalal et al.
Importance and objective: Chronic opioid use may increase the risk of complications in patients with inflammatory bowel disease (IBD). Rheumatologic illness has been identified as a risk factor for chronic opioid use in I...
Fibroblast-Mediated MMP2 Contribution to Nonresponse in Anti-TNFα Therapy for Crohn's Disease [0.03%]
成纤维细胞介导的MMP2在抗TNFα治疗克罗恩病无应答中的作用
Danshu Wang,Dehao Zhu,Xiangyu Zhao et al.
Danshu Wang et al.
Background: Despite the transformative impact of biologics on the treatment of inflammatory bowel disease (IBD) in recent years, a substantial proportion of patients remain unresponsive to these advanced therapies. Overco...
Barriers and Opportunities for Resilience Programs in IBD: Insights From the SMART Project [0.03%]
SMART项目中关于IBD患者恢复计划的障碍与机遇的见解
Victor Chedid,Shayla Schoenoff,Abby Webb et al.
Victor Chedid et al.
Raquel Oliveira,Joana Roseira
Raquel Oliveira
This editorial discusses the post-hoc analysis by Dubinsky et al. evaluating upadacitinib's efficacy and safety by baseline corticosteroid use in Crohn's disease, highlighting its corticosteroid-sparing potential, the need for standardized ...
Giulia Valdiserra,Massimo C Fantini,Agnese Favale et al.
Giulia Valdiserra et al.
This commentary examines the progressive decline in biologic efficacy in inflammatory bowel disease, highlighting pharmacologic, immunologic, and cellular mechanisms of resistance. It advocates for early, biomarker-guided, and mechanistical...